Developing a flexible platform for creating vaccines
Official title: A Tunable Nanophage Platform for Vaccine Development
Funded at University of Colorado Denver · NIH-11136699 · Data updated 2026-11-12
This study is working on a new kind of vaccine that uses tiny particles to quickly create and test vaccines for diseases like COVID-19, aiming to give people faster access to safe and long-lasting protection against viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | August 20, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $726,000 |
| NIH project number | 1R56AI186400-01 |
| Project ID | NIH-11136699 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for COVID-19 and other emerging viral infections, including those with compromised immune systems.
✕Less likely to help
Patients who are not at risk for viral infections or those who have already been vaccinated may not receive direct benefits from this research.
What this research studies
This research focuses on creating a new type of vaccine platform using engineered nanoparticles called nanophages. These nanophages can be quickly modified to display various antigens, allowing for rapid testing of potential vaccines against emerging infectious diseases like COVID-19 and other coronaviruses. The approach includes advanced techniques to ensure that the vaccine candidates are stable and effective, potentially leading to single-shot vaccines that provide long-lasting immunity. Patients may benefit from faster access to effective vaccines against current and future viral threats.
Why it matters
Potential benefit: If successful, this research could lead to the rapid development of effective vaccines for COVID-19 and similar viral infections.
How similar studies have gone: Previous research has shown promise in using nanoparticle platforms for vaccine development, indicating a potential for success with this novel approach.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Catalano, Carlos Enrique — University of Colorado Denver
- Study coordinator: Catalano, Carlos Enrique
Related research
Other NIH-funded projects on the same topics.
-
Understanding how alcohol and how couples talk about consent affect intimate partner sexual violence
This project studies how alcohol use and how partners communicate about consent influence intimate partner sexual violence among sexual minority and heterosexual couples.
-
How proteins change and move as heart cells develop
This grant aims to map how protein turnover changes as human iPSCs turn into cardiomyocytes and other cell types, using new labeling and mass-spectrometry methods.
-
Center for Health, Work and Environment
A national center dedicated to improving health in people who work, by studying how jobs affect well-being and safety.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Expanded antibody-based clues to TB risk in people with HIV
A clinician-scientist seeks to understand how antibodies in people with HIV may drive the progression from latent TB to active TB, with the goal of identifying clues that could guide future care.
-
Human Trisome Project in Latin America Network
A large, multi-site study of people with Down syndrome across Latin America to better understand health and aging in DS.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.